文献速递中枢神经肿瘤放疗放疗物理与技术

1.5T磁共振直线加速器监测胶质母细胞瘤放化疗期间的动态变化

Monitoring glioblastoma dynamics during chemoradiation on the 1.5 T magnetic resonance imaging-linear accelerator.
PubMed 文献 · Clin Transl Radiat Oncol · 2026-05-28

调整线性混合效应模型显示,早期进展者从F7起Vrel更高,从F19起dmigrate更高,提示治疗中影像可用于风险分层。

要点

  • 早期进展者从F7起T2/FLAIR体积变化(Vrel)显著高于非早期进展者(F15差38%,p=0.004)。
  • 早期进展者从F19起迁移距离(dmigrate)更高(差5.9mm,p=0.02),F30差8.5mm(p=0.01)。
  • 治疗结束时Vrel≥10%者中83%为早期进展者,dmigrate≥10mm者中69%为早期进展者。

核心结论

  • 系列1.5T MR-Linac成像可纵向评估胶质母细胞瘤放化疗期间T2/FLAIR异常的体积变化与空间迁移。
  • Vrel和dmigrate的更大增加与早期进展相关,支持治疗中影像用于风险适应性MR引导放疗策略的潜在价值。

研究设计与样本

  • 在基线(F0)、选定治疗分次及放疗后1个月(PM1)勾画T2/FLAIR异常信号区域。
  • 以相对F0的体积百分比变化(Vrel)和相对F0的最大线性位移(dmigrate)量化肿瘤动态。
  • 按放化疗后6个月内是否进展分为早期进展者(12例)与非早期进展者。
  • 采用线性混合效应模型评估按早期进展状态、甲基化状态和切除范围分组的纵向差异。

主要发现

  • 调整线性混合效应模型中,早期进展者从F7起Vrel高于非早期进展者(所有p<0.025),治疗后期差异更大(F15:38%,p=0.004;F30:104%,p=0.019)。
  • Vrel中位数在F1为2%、F15为2%、F30为18%。
  • dmigrate中位数从F1的5.0mm增至F30的12.6mm,早期进展者从F19起更高(差5.9mm,p=0.02),F30差8.5mm(p=0.01)。
  • 治疗结束时Vrel≥10%见于12/28例(43%),dmigrate≥10mm见于13/28例(46%)。
  • Vrel≥10%的患者中10/12例(83%)为早期进展者,dmigrate≥10mm的患者中9/13例(69%)为早期进展者。

临床怎么用

  • 可利用1.5T MR-Linac在放化疗期间重复成像,纵向监测T2/FLAIR异常的体积变化与空间迁移。
  • 治疗中Vrel和dmigrate的增大可提示早期进展风险,或有助于筛选适合风险适应性MR引导放疗策略的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Magnetic resonance-guided radiotherapy enables repeated on-treatment imaging during chemoradiotherapy for glioblastoma (GBM), providing an opportunity to study dynamic tumor changes. We evaluated longitudinal volumetric change and spatial migration of T2/FLAIR signal abnormalities during treatment using a 1.5 T MR-Linac and examined their association with early disease progression. METHODS: GBM patients suitable for chemoradiation on a 1.5 T MR-Linac were prospectively enrolled. Regions of T2/FLAIR signal abnormalities were contoured at baseline (F0), during selected treatment fractions, and at one-month post-radiotherapy (PM1). Tumor dynamics were quantified using percentage change in volume relative to F0 (Vrel) and migration distance (dmigrate), defined as the maximum linear displacement relative to F0. Patients were classified as early progressors (disease progression within 6 months after chemoradiation) or non-early progressors. Linear mixed-effects models evaluated longitudinal differences by early progression status, methylation, and extent of resection. RESULTS: Thirty-three patients were included; 28 had ≥ 6 months follow-up and 12 were classified as early progressors. In adjusted linear mixed-effects models, Vrel was higher in early progressors than in non-early progressors from F7 onward (all p < 0.025), with larger differences later in treatment (F15: 38%, p = 0.004; F30: 104%, p = 0.019). Median Vrel was 2% at F1, 2% at F15, and 18% at F30. Median dmigrate increased from 5.0 mm at F1 to 12.6 mm at F30 and was higher in early progressors from F19 onward (difference 5.9 mm, p = 0.02) and at F30 (8.5 mm, p = 0.01). At end of treatment, Vrel ≥ 10% occurred in 12/28 patients (43%) and dmigrate ≥ 10 mm in 13/28 (46%). Among patients with Vrel ≥ 10%, 10/12 (83%) were early progressors; among those with dmigrate ≥ 10 mm, 9/13 (69%) were early progressors. CONCLUSION: Serial 1.5 T MR-Linac imaging enables longitudinal assessment of T2/FLAIR abnormality volume (Vrel) and spatial migration (dmigrate) during chemoradiotherapy for glioblastoma. Greater increases in Vrel and dmigrate were associated with early progression, supporting the potential role of on-treatment imaging in informing risk-adapted MR-guided radiotherapy strategies.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Jamora K, Mathieu D, Fong SC, et al. Monitoring glioblastoma dynamics during chemoradiation on the 1.5 T magnetic resonance imaging-linear accelerator. Clin Transl Radiat Oncol. 2026. PMID: 42327915. doi:10.1016/j.ctro.2026.101200

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。